<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: Some EBV-directed therapies are predicted to be effective only when lytic <z:mp ids='MP_0001799'>viral</z:mp> replication occurs </plain></SENT>
<SENT sid="1" pm="."><plain>We studied whether <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> chemotherapy induces EBV to switch from latent to lytic phases of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> in a series of EBV-associated Burkitt <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: Children with first presentation of an expanding, solid maxillary or mandibular mass consistent with Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> underwent fine-needle <z:hpo ids='HP_0002835'>aspiration</z:hpo> just prior to the initiation of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> therapy and again 1 to 5 days later </plain></SENT>
<SENT sid="3" pm="."><plain>Aspirated cells were examined for latent and lytic <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> using in situ hybridization to EBV-encoded <z:chebi fb="40" ids="33697">RNA</z:chebi> (EBER), immunohistochemical analysis of the lytic EBV proteins BZLF1 and BMRF1, reverse transcription PCR targeting BZLF1 transcripts, and EBV <z:mp ids='MP_0001799'>viral</z:mp> load measurement by quantitative PCR </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Among 21 <z:hpo ids='HP_0002665'>lymphomas</z:hpo> expressing EBER prior to chemotherapy, 9 of 10 still expressed EBER on day 1 after therapy whereas only 2 of 11 (18%) specimens still expressed EBER at days 3 to 5, implying that chemotherapy was fairly effective at eliminating latently infected cells </plain></SENT>
<SENT sid="5" pm="."><plain>Neither of the lytic products, BZLF1 or BMRF1, were significantly upregulated at the posttherapy time points examined </plain></SENT>
<SENT sid="6" pm="."><plain>However, EBV genomic copy number increased in 5 of 10 samples 1 day after treatment began, suggesting that <z:mp ids='MP_0001799'>viral</z:mp> replication occurs within the first 24 hours </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi> may induce the lytic phase of <z:e sem="disease" ids="C0149678" disease_type="Disease or Syndrome" abbrv="">EBV infection</z:e> and is fairly effective in diminishing EBER-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells within 5 days </plain></SENT>
<SENT sid="8" pm="."><plain>These findings provide the rationale for a trial testing synergistic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell killing using <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> with a drug like <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> targeting lytically infected cells </plain></SENT>
</text></document>